Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria

Since conventional 14-day primaquine (PMQ) radical cure of vivax malaria is associated with poor compliance and as total dose, not therapy duration, determines efficacy, a preliminary pharmacokinetic study of two doses (0.5 and 1.0 mg/kg) was conducted in 28 healthy glucose-6-phosphate dehydrogenase...

Full description

Bibliographic Details
Main Authors: Moore, Brioni, Salman, S., Benjamin, J., Page-Sharp, Madhu, Robinson, L., Waita, E., Batty, Kevin, Siba, P., Mueller, I., Davis, T., Betuela, I.
Format: Journal Article
Published: American Society for Microbiology 2014
Online Access:http://hdl.handle.net/20.500.11937/9960
_version_ 1848746100081557504
author Moore, Brioni
Salman, S.
Benjamin, J.
Page-Sharp, Madhu
Robinson, L.
Waita, E.
Batty, Kevin
Siba, P.
Mueller, I.
Davis, T.
Betuela, I.
author_facet Moore, Brioni
Salman, S.
Benjamin, J.
Page-Sharp, Madhu
Robinson, L.
Waita, E.
Batty, Kevin
Siba, P.
Mueller, I.
Davis, T.
Betuela, I.
author_sort Moore, Brioni
building Curtin Institutional Repository
collection Online Access
description Since conventional 14-day primaquine (PMQ) radical cure of vivax malaria is associated with poor compliance and as total dose, not therapy duration, determines efficacy, a preliminary pharmacokinetic study of two doses (0.5 and 1.0 mg/kg) was conducted in 28 healthy glucose-6-phosphate dehydrogenase-normal Papua New Guinean children aged 5-12 years to facilitate development of abbreviated high-dose regimens. Dosing was with food and directly observed, and venous blood samples were drawn over 168 h post-dose. Detailed safety monitoring was performed including hepatorenal function, and hemoglobin and methemaglobin concentrations. Plasma concentrations of PMQ and its metabolite carboxyprimaquine (CPMQ) were determined by liquid-chromatography/mass spectrometry and analyzed using population pharmacokinetic methods. The derived models were used in simulations. Both single-dose regimens were well tolerated with no changes in safety parameters. The mean PMQ central volume of distribution and clearance relative to bioavailability (200 liters/70 kg and 24.6 liters/h/70 kg) were within published ranges for adults. The median predicted maximal concentration (Cmax) for both PMQ and CPMQ after last dose of a 1.0 mg/kg 7-day PMQ regimen were approximately double those at the end of 14 days of 0.5 mg/kg daily, while a 1.0 mg/kg twice daily regimen resulted in a 2.38 and 3.33 times higher Cmax for PMQ and CPMQ, respectively. All predicted median Cmax concentrations were within ranges in adult high-dose studies that also showed acceptable safety and tolerability. The present pharmacokinetic data, the first for PMQ in children, show that further studies of abbreviated high-dose regimens are feasible in this age-group.
first_indexed 2025-11-14T06:27:53Z
format Journal Article
id curtin-20.500.11937-9960
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:27:53Z
publishDate 2014
publisher American Society for Microbiology
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-99602023-02-22T06:24:15Z Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria Moore, Brioni Salman, S. Benjamin, J. Page-Sharp, Madhu Robinson, L. Waita, E. Batty, Kevin Siba, P. Mueller, I. Davis, T. Betuela, I. Since conventional 14-day primaquine (PMQ) radical cure of vivax malaria is associated with poor compliance and as total dose, not therapy duration, determines efficacy, a preliminary pharmacokinetic study of two doses (0.5 and 1.0 mg/kg) was conducted in 28 healthy glucose-6-phosphate dehydrogenase-normal Papua New Guinean children aged 5-12 years to facilitate development of abbreviated high-dose regimens. Dosing was with food and directly observed, and venous blood samples were drawn over 168 h post-dose. Detailed safety monitoring was performed including hepatorenal function, and hemoglobin and methemaglobin concentrations. Plasma concentrations of PMQ and its metabolite carboxyprimaquine (CPMQ) were determined by liquid-chromatography/mass spectrometry and analyzed using population pharmacokinetic methods. The derived models were used in simulations. Both single-dose regimens were well tolerated with no changes in safety parameters. The mean PMQ central volume of distribution and clearance relative to bioavailability (200 liters/70 kg and 24.6 liters/h/70 kg) were within published ranges for adults. The median predicted maximal concentration (Cmax) for both PMQ and CPMQ after last dose of a 1.0 mg/kg 7-day PMQ regimen were approximately double those at the end of 14 days of 0.5 mg/kg daily, while a 1.0 mg/kg twice daily regimen resulted in a 2.38 and 3.33 times higher Cmax for PMQ and CPMQ, respectively. All predicted median Cmax concentrations were within ranges in adult high-dose studies that also showed acceptable safety and tolerability. The present pharmacokinetic data, the first for PMQ in children, show that further studies of abbreviated high-dose regimens are feasible in this age-group. 2014 Journal Article http://hdl.handle.net/20.500.11937/9960 10.1128/AAC.01437-13 American Society for Microbiology unknown
spellingShingle Moore, Brioni
Salman, S.
Benjamin, J.
Page-Sharp, Madhu
Robinson, L.
Waita, E.
Batty, Kevin
Siba, P.
Mueller, I.
Davis, T.
Betuela, I.
Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria
title Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria
title_full Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria
title_fullStr Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria
title_full_unstemmed Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria
title_short Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria
title_sort pharmacokinetic properties of single-dose primaquine in papua new guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria
url http://hdl.handle.net/20.500.11937/9960